Related Experiment Videos
Lower limb function and quality of life after ILP for soft-tissue sarcoma
Lars Erik Podleska1, Nevda Kaya2, Farhad Farzaliyev2
1Sarcoma Surgery Division, Department of General, Visceral and Transplantation Surgery, University Hospital of Essen and Sarcoma Center at the West German Cancer Center (WTZ), University of Duisburg-Essen, Hufelandstr. 55, 45147, Essen, Germany. lars.podleska@uk-essen.de.
World Journal of Surgical Oncology
|April 14, 2017
Summary
Isolated limb perfusion with TNF-alpha and melphalan (TM-ILP) offers effective limb salvage for soft-tissue sarcomas. Patients treated with TM-ILP reported quality of life comparable to the general population, despite some functional impairments.
Area of Science:
- Oncology
- Surgical Oncology
- Quality of Life Research
Background:
- Isolated limb perfusion with TNF-alpha and melphalan (TM-ILP) combined with tumor resection is a key treatment for non-resectable extremity soft-tissue sarcomas.
- This approach achieves limb salvage rates exceeding 80%.
Purpose of the Study:
- To evaluate the quality of life (QoL) in patients undergoing TM-ILP for soft-tissue sarcomas.
- To assess long-term QoL outcomes and compare them to relevant reference groups.
Main Methods:
- Retrospective analysis of 27 patients with non-resectable soft-tissue sarcomas of the leg treated with TM-ILP and limb-sparing surgery.
- Utilized the Quality of Life Questionnaire (QLQ-C30) and the German Short Musculoskeletal Function Assessment (SMFA-D) for QoL and functional assessment.
- Compared patient outcomes to general population, cancer patient, and historical amputation group data.
Main Results:
- Global health status/QoL in the TM-ILP group was comparable to the general population and amputation groups, and superior to cancer patients overall.
- Patients exhibited functional impairments post-TM-ILP compared to healthy individuals.
- No significant decline in QoL was observed over extended follow-up periods.
Conclusions:
- TM-ILP is a viable limb-sparing option, supporting patient quality of life.
- Further research is warranted to fully understand the long-term QoL implications of TM-ILP.